Robin Peter

UC Berkeley

“Microscale dose heterogeneity of 225Ac-based radiopharmaceuticals in a preclinical prostate cancer mouse model”

Alpha-particle therapy is a promising alternative treatment for metastatic cancers that requires improved dose characterization and imaging to be clinically safe and relevant. This work demonstrates image processing and analytical methods to gather dose information from preclinical alpha particle research using an iQID camera device.


Due to the short alpha-particle range and often heterogeneous distribution of targeting agents, cancer treatment using alpha-emitting radiopharmaceuticals can be subject to dose heterogeneity within target and non-target tissues. Without micro-scale characterization, high-uptake dose-limiting regions within nonuniform organs at risk can go unidentified. To help identify vulnerable sub-organ regions in humans, this work studies the microscopic distribution of 225Ac-radiopharmaceutical alpha-particle dose in murine models of prostate cancer (PCa) using microscale ex vivo dosimetry. Overall, this study models how quantitative digital autoradiography-based dosimetry can examine the effects of microscale dose heterogeneity on treatment targets and organs.

8 + 5 =